IL316100A - Methods for treating leukocytosis, endothelial dysfunction, and carditis using lipid-binding protein-based complexes - Google Patents
Methods for treating leukocytosis, endothelial dysfunction, and carditis using lipid-binding protein-based complexesInfo
- Publication number
- IL316100A IL316100A IL316100A IL31610024A IL316100A IL 316100 A IL316100 A IL 316100A IL 316100 A IL316100 A IL 316100A IL 31610024 A IL31610024 A IL 31610024A IL 316100 A IL316100 A IL 316100A
- Authority
- IL
- Israel
- Prior art keywords
- carditis
- methods
- binding protein
- endothelial dysfunction
- lipid binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328210P | 2022-04-06 | 2022-04-06 | |
| PCT/IB2023/000183 WO2023194798A1 (en) | 2022-04-06 | 2023-04-06 | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316100A true IL316100A (en) | 2024-12-01 |
Family
ID=86732365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316100A IL316100A (en) | 2022-04-06 | 2023-04-06 | Methods for treating leukocytosis, endothelial dysfunction, and carditis using lipid-binding protein-based complexes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250255931A1 (https=) |
| EP (1) | EP4504233A1 (https=) |
| JP (1) | JP2025512987A (https=) |
| KR (1) | KR20240171131A (https=) |
| CN (1) | CN119317440A (https=) |
| AU (1) | AU2023251245A1 (https=) |
| CA (1) | CA3247588A1 (https=) |
| IL (1) | IL316100A (https=) |
| MX (1) | MX2024012302A (https=) |
| WO (1) | WO2023194798A1 (https=) |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| CA2185450A1 (en) | 1994-03-22 | 1995-09-28 | Patrick Tso | Eating suppressant peptides |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| DE60117781T2 (de) | 2000-04-21 | 2006-11-23 | Amgen Inc., Thousand Oaks | Peptidderivate des apolipoproteins-a1/aii |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| BR0115257A (pt) | 2000-11-10 | 2003-08-12 | Proteopharma Aps | Análogos de apolipoproteìna |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| DE60226881D1 (de) | 2001-08-20 | 2008-07-10 | Zlb Bioplasma Ag | High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| JP2006507223A (ja) | 2002-05-17 | 2006-03-02 | エスペリオン セラピューティクス，インコーポレイテッド | 脂質代謝異常疾患の治療方法 |
| EP1545576A2 (en) | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| TWI433693B (zh) | 2003-02-14 | 2014-04-11 | Childrens Hosp & Res Ct Oak | 親脂藥物傳送媒介物及其使用方法 |
| KR101185609B1 (ko) | 2004-07-16 | 2012-09-24 | 트러스티즈 오브 터프츠 칼리지 | 아포리포단백질 ａ１ 미메틱 및 이의 용도 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| EP1917278A2 (en) | 2005-08-26 | 2008-05-07 | Cerenis Therapeutics Holding SA | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| US20080293102A1 (en) | 2007-02-28 | 2008-11-27 | Cerenis Therapeutics Holding, S.A. | Compositions and methods for producing apolipoprotein |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| WO2009055538A1 (en) | 2007-10-23 | 2009-04-30 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein a-1 and mimetic peptides |
| JP5719783B2 (ja) | 2009-02-16 | 2015-05-20 | セレニス セラピューティクス ホールディング エスアー | アポリポタンパクａ−ｉ模倣物 |
| US20130137628A1 (en) | 2010-05-11 | 2013-05-30 | Esperion Therapeutics, Inc. | Dimeric Oxidation-Resistant Apolipoprotein A1 Variants |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| EP3842443B1 (en) | 2013-03-15 | 2025-02-19 | Cerenis Therapeutics Holding SA | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| US11752163B2 (en) * | 2020-04-16 | 2023-09-12 | Abionyx Pharma Sa | CER-001 therapy for treating kidney disease |
| MX2022012969A (es) * | 2020-04-16 | 2022-11-09 | Abionyx Pharma Sa | Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos. |
-
2023
- 2023-04-06 CN CN202380044954.XA patent/CN119317440A/zh active Pending
- 2023-04-06 US US18/854,185 patent/US20250255931A1/en active Pending
- 2023-04-06 JP JP2024559383A patent/JP2025512987A/ja active Pending
- 2023-04-06 CA CA3247588A patent/CA3247588A1/en active Pending
- 2023-04-06 AU AU2023251245A patent/AU2023251245A1/en active Pending
- 2023-04-06 IL IL316100A patent/IL316100A/en unknown
- 2023-04-06 WO PCT/IB2023/000183 patent/WO2023194798A1/en not_active Ceased
- 2023-04-06 KR KR1020247036482A patent/KR20240171131A/ko active Pending
- 2023-04-06 EP EP23729835.1A patent/EP4504233A1/en active Pending
-
2024
- 2024-10-03 MX MX2024012302A patent/MX2024012302A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240171131A (ko) | 2024-12-06 |
| CN119317440A (zh) | 2025-01-14 |
| JP2025512987A (ja) | 2025-04-22 |
| EP4504233A1 (en) | 2025-02-12 |
| CA3247588A1 (en) | 2023-10-12 |
| US20250255931A1 (en) | 2025-08-14 |
| WO2023194798A1 (en) | 2023-10-12 |
| AU2023251245A1 (en) | 2024-11-14 |
| MX2024012302A (es) | 2025-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550348A1 (en) | Materials and methods for improved single chain variable fragments | |
| EP3635363C0 (en) | FABRIC COLORING, RELAXING AND TREATMENT PROCESS | |
| HK1244232A1 (zh) | 用於治疗肺纤维化的血管紧张素ii受体激动剂 | |
| EA200801521A1 (ru) | Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения | |
| IL312220A (en) | Protein inhibitors containing the prolyl hydroxylase region and their uses | |
| EP3623477A4 (en) | RECOMBINANT VECTOR WITH CELLULOSE BINDING DOMAIN AND METHOD OF ISOLATION AND PURIFICATION OF PROTEIN USING THE SAME VECTOR | |
| IL316100A (en) | Methods for treating leukocytosis, endothelial dysfunction, and carditis using lipid-binding protein-based complexes | |
| EP4077374A4 (en) | POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME | |
| GB201803905D0 (en) | Methods for treating tobacco, material, apparatus for treating tobacco material, treated tobacco material and uses thereof | |
| EP4041282A4 (en) | METHODS OF USE OF IL-33 PROTEIN IN THE TREATMENT OF CANCER | |
| HK40124125A (en) | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes | |
| WO2006129843A3 (en) | Bispecific capturing molecule | |
| IL288953A (en) | Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors | |
| GB2422834B (en) | MHC oligomer and method of making the same | |
| IL304745A (en) | Complement c3 antigen-binding proteins | |
| MX2021008009A (es) | Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico. | |
| WO2021231803A3 (en) | Binding molecules for covid-19 treatment | |
| IL317446A (en) | Methods for treating acute conditions using complexes based on lipid-binding proteins | |
| DK1844333T3 (da) | Fremgangsmåde til eftervisning og fjernelse af endotoxiner | |
| EP3831211C0 (de) | Verfahren zum behandeln von kaffeebohnen | |
| WO2024058987A3 (en) | Polypeptides effective against multiple coronaviruses | |
| GB202002790D0 (en) | Methods for treating tobacco material, apparatus for treating tobacco material, treated tobacco material and uses thereof | |
| AU2024217776A1 (en) | Methods for treating glioblastoma | |
| IL316110A (en) | Methods for treating eye diseases using complexes based on fat-binding protein | |
| IL317448A (en) | Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins |